Digistain

Digistain is dedicated to transforming breast cancer diagnostics, offering hope to millions affected worldwide. Originating from pioneering research at Imperial College London, Digistain's technology is poised to revolutionize how breast cancer is diagnosed and treated.

The current diagnostic landscape presents significant challenges. Annually, 2.3 million individuals are diagnosed with breast cancer globally. Following surgery, a substantial 60% of patients are recommended for genomic testing. However, this process is often expensive, time-consuming, and dominated by a single U.S. lab, costing approximately $4,000 and requiring nearly two months for results. Consequently, only a small fraction of patients (around 5%) undergo this crucial testing. The remainder often proceed with chemotherapy, a treatment that can be more detrimental than the cancer itself in a significant number of cases.

Digistain offers a solution by enabling hospitals to conduct in-house analysis of patient samples using existing equipment, enhanced by their innovative technology. This approach provides near-instantaneous data for informed decision-making, drastically reducing the month-long wait times associated with current methods. At the core of Digistain's technology is a proprietary algorithm that identifies a unique spectral fingerprint of the tumor in the infrared spectrum, generating a personalized risk score. This score empowers oncologists to select the most effective and individualized treatment plans, potentially minimizing the use of unnecessary chemotherapy and its associated side effects.

Digistain's solution not only disrupts the technological status quo but also enhances accessibility. A government-commissioned study demonstrated clinical evidence comparable to the market leader, but at a significantly reduced cost and time. Already impacting clinical practice globally and securing insurance reimbursement at leading cancer centers, Digistain's technology represents a paradigm shift in cancer care. Supported by institutions like the NHS, Y Combinator, and the European Investment Bank, Digistain is actively creating a future where life-saving diagnostics are more accessible and effective, improving outcomes for cancer patients worldwide.